Hikma expands Ohio site it got in Roxane deal, adding 95 workers

Hikma is expanding the large manufacturing site in Columbus, OH, it acquired in 2015 from Boehringer Ingelheim.

Jordan-based Hikma is expanding the manufacturing and distribution operations at a large solid-dose manufacturing site it picked up in 2015 from Boehringer Ingelheim, adding about 100 jobs in the process. 

HIkma’s West-Ward generics division has committed to adding 65 jobs as part of an expansion of the solid dose plant in Columbus, OH, in exchange for a 7-year tax credit worth up to $100,000 that was granted this week by the Ohio Tax Credit Authority, Columbus Business First reports.

Hikma got the 875,000-square-foot manufacturing site in Columbus with its $2.65 billion buyout in 2015 of Roxanne Laboratories, the U.S. generics business of Germany’s Boehringer Ingelheim. Hikma folded the new operation into its U.S.-based West-Ward, which produces both sterile injectables and solid dose products.

Work on a 30,300-square-foot, two-story expansion to the west Columbus plant began last summer, Business First says, and  is expected to open in phases through May 2018.

In addition, West-Ward is building a 276,000-square-foot distribution facility in nearby Obetz where it will add another 30 jobs.